IL-21 in the pathogenesis and treatment of skin diseases

Journal of Dermatological Science

Volumn 60, Issue 2, 2010, Pages 61-66

  Costanzo, A ^a   Chimenti, Maria Sole ^a   Botti, Elisabetta ^a   Caruso, Roberta ^a   Sarra, Massimiliano ^a   Monteleone, Giovanni ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Atopic dermatitis; IL 21; Immune mediated skin diseases; Melanoma; Psoriasis

Indexed keywords

INTERLEUKIN 21; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 21; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALOPECIA AREATA; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; AUTOIMMUNITY; CLINICAL TRIAL; DRUG ERUPTION; FLU LIKE SYNDROME; HUMAN; INFLAMMATORY CELL; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOCYTOPENIA; MELANOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; DERMATITIS, ATOPIC; HUMANS; INTERLEUKINS; MELANOMA; MICE; SKIN DISEASES; SKIN NEOPLASMS;

EID: 77958512341     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.08.016     Document Type: Review

References (58)

1. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
2. Harada M., Magara-Koyanagi K., Watarai H., Nagata Y., Ishii Y., Kojo S., et al. IL-21-induced B cell apoptosis mediated by natural killer T cells suppresses IgE responses. J Exp Med 2006, 203:2929-2937.
3. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P., et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007, 13:3630-3636.
4. Zeng R., Spolski R., Casas E., Zhu W., Levy D.E., Leonard W.J. The molecular basis of IL-21-mediated proliferation. Blood 2007, 109:4135-4142.
5. Gagnon J., Ramanathan S., Leblanc C., Ilangumaran S. Regulation of IL-21signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8(+) T lymphocytes. Cell Signal 2007, 19:806-816.
6. Ettinger R., Sims G.P., Fairhurst A.M., Robbins R., da Silva Y.S., Spolski R., et al. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol 2005, 175:7867-7879.
7. Li Y., Bleakley M., Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005, 175:2261-2269.
8. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36:661-670.
9. Korn T., Bettelli E., Gao W., Awasthi A., Jäger A., Strom T.B., et al. IL-21initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
10. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
11. Strengell M., Sareneva T., Foster D., Julkunen I., Matikainen S. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J Immunol 2002, 169:3600-3605.
12. Peluso I., Fantini M.C., Fina D., Caruso R., Boirivant M., MacDonald T.T., et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007, 178:732-739.
13. Brady J., Hayakawa Y., Smyth M.J., Nutt S.L. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004, 172:2048-2058.
14. Caruso R., Botti E., Sarra M., Esposito M., Stolfi C., Diluvio L., et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15:1013-1015.
15. Caruso R., Fina D., Peluso I., Stolfi C., Fantini M.C., Gioia V., et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007, 132:166-175.
16. Monteleone G., Caruso R., Fina D., Peluso I., Gioia V., Stolfi C., et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006, 55:1774-1780.
17. Caruso R., Fina D., Peluso I., Fantini M.C., Tosti C., Del Vecchio Blanco G., et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol 2007, 178:5957-5965.
18. Li J., Shen W., Kong K., Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006, 64:515-522.
19. Ozaki K., Hishiya A., Hatanaka K., Nakajima H., Wang G., Hwu P., et al. Overexpression of interleukin 21 induces expansion of hematopoietic progenitor cells. Int J Hematol 2006, 84:224-230.
20. Perl A., Fernandez D.R., Telarico T., Doherty E., Francis L., Phillips P.E. T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol 2009, 21:454-464.
21. Izui S., Ibnou-Zekri N., Fossati-Jimack L., Iwamoto M. Lessons from BXSB and related mouse models. Int Rev Immunol 2000, 19:447-472.
22. Ozaki K., Spolski R., Ettinger R., Kim H.P., Wang G., Qi C.F., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004, 173:5361-5371.
23. Herber D., Brown T.P., Liang S., Young D.A., Collins M., Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007, 178:3822-3830.
24. Wong C.K., Wong P.T., Tam L.S., Li E.K., Chen D.P., Lam C.W. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 2010, 30:45-52.
25. Festen E.A., Goyette P., Scott R., Annese V., Zhernakova A., Lian J., et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009, 58:799-804.
26. van Heel D.A., Franke L., Hunt K.A., Gwilliam R., Zhernakova A., Inouye M., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39:827-829.
27. Liu Y., Helms C., Liao W., Zaba L.C., Duan S., Gardner J., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4:e1000041.
28. Asano K., Ikegami H., Fujisawa T., Nishino M., Nojima K., Kawabata Y., et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007, 68:384-391.
29. Teixeira V.H., Pierlot C., Migliorini P., Balsa A., Westhovens R., Barrera P., et al. Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Res Ther 2009, 11:R45.
30. Chatterjee R., Batra J., Ghosh B. A common exonic variant of interleukin21 confers susceptibility to atopic asthma. Int Arch Allergy Immunol 2009, 148:137-146.
31. Sawalha A.H., Kaufman K.M., Kelly J.A., Adler A.J., Aberle T., Kilpatrick J., et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008, 67:458-461.
32. Nestle F.O., Kaplan D.H., Psoriasis B.J. N Engl J Med 2009, 361:496-509.
33. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
34. Strengell M., Julkunen I., Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J Leukoc Biol 2004, 76:416-422.
35. Niu X., He D., Zhang X., Yue T., Li N., Zhang J.Z., et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010, 71:334-341.
36. Jang E., Cho S.H., Park H., Paik D.J., Kim J.M., Youn J. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+. J Immunol 2009, 182:4649-4656.
37. Vollmer T.L., Liu R., Price M., Rhodes S., La C.A., Shi F.D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005, 174:2696-2701.
38. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
39. Nickoloff B.J. Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol 2001, 28:57-64.
40. Monteleone G., Pallone F., Macdonald T.T. Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 2009, 30:441-447.
41. Monteleone G., Pallone F., MacDonald T.T. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008, 29:290-294.
42. Novak N., Bieber T., Leung D.Y. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003, 112(Suppl):S128-S139.
43. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121:1337-1343.
44. Weidinger S., Illig T., Baurecht H., Irvine A.D., Rodriguez E., Diaz-Lacava A., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006, 118:214-219.
45. Jin H., Oyoshi M.K., Le Y., Bianchi T., Koduru S., Mathias C.B., et al. IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 2009, 119:47-60.
46. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207.
47. Gilhar A., Landau M., Assy B., Ullmann Y., Shalaginov R., Serafimovich S., et al. Transfer of alopecia areata in the human scalp graft/Prkdc(scid) (SCID) mouse system is characterized by a TH1 response. Clin Immunol 2003, 106:181-187.
48. McDonagh A.J., Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002, 27:405-409.
49. Jackow C., Puffer N., Hordinsky M., Nelson J., Tarrand J., Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment?. J Am Acad Dermatol 1998, 38:418-425.
50. Martinez-Mir A., Zlotogorski A., Gordon D., Petukhova L., Mo J., Gilliam T.C., et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007, 80:316-328.
51. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., Shimomura Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
52. Rasmussen M.A., Colding-Jørgensen M., Hansen L.T., Bro R. Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol 2010, 69:379-390.
53. Hashmi M.H., Van Veldhuizen P.J. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther 2010, 10:807-817.
54. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005, 201:139-148.
55. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003, 63:9016-9022.
56. Søndergaard H., Galsgaard E.D., Bartholomaeussen M., Straten P.T., Odum N., Skak K. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother 2010, 33:236-249.
57. Zhao F., Dou J., He X.F., Wang J., Chu L., Hu W., et al. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 2010, 28:2846-2852.
58. Williams P., Rafei M., Bouchentouf M., Raven J., Yuan S., Cuerquis J., et al. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 2010, 18:1293-1301.